News NANOBIOTIX ANNOUNCES FIRST EVER RADIOENHANCER TO RECEIVE EUROPEAN MARKET APPROVAL Apr 04, 2019 Posted by Nanobiotix
News Combination of first-in-class NBTXR3, radiotherapy, and anti-PD-1 immunotherapy demonstrate efficacy in treating resistant pre-clinical in vivo models of lung cancer Apr 03, 2019 Posted by Nanobiotix
News Charles River Laboratories Highlights Commitment to Oncology Research at 2019 AACR Annual Meeting Apr 02, 2019 Posted by Charles River Laboratories
News Cyteir Therapeutics Announces New Data Demonstrating Lead Compound CYT-0851 is Active Against Lymphomas and Solid Tumors; Synergistic with PARP Inhibitors Mar 31, 2019
News 5TH Annual Science of Stability Conference Announces Location and Themes Mar 29, 2019 Posted by FreeThink Technologies, Inc.